Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Sponsor

Tempest Therapeutics (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04344795

Collaborator

(none)

175

Enrollment

Locations

Arms

52.9

Anticipated Duration (Months)

19.4

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study of TPST-1495 as a single agent and in combination with pembrolizumab to determine its maximum tolerated dose (MTD) and or recommended Phase 2 dose (RP2D), safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity in subjects with advanced solid tumors. Subjects with all histologic types of solid tumors are eligible for the escalation and dose-finding portions of the study. However, the preferred tumor types for enrollment are colorectal cancer (CRC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial cancer, endometrial cancer, and gastroesophageal junction (GEJ) or gastric adenocarcinoma. Enrollment in the expansion cohorts is limited to the following tumor types: endometrial, SCCHN, CRC, and a basket cohort in subjects selected for an activating mutation in PIK3Ca.

Condition or Disease	Intervention/Treatment	Phase
Solid Tumor Colorectal Cancer Non Small Cell Lung Cancer Squamous Cell Carcinoma of Head and Neck Urothelial Carcinoma Endometrial Cancer Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Solid Tumors With PIK3Ca Mutation	Drug: TPST-1495 twice daily Drug: TPST-1495 once daily or on intermittent schedule Drug: Pembrolizumab	Phase 1

Detailed Description

This is a first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study of TPST-1495 as a single agent and in combination with pembrolizumab to determine its MTD, safety, tolerability, pharmacokinetics (PD), pharmacodynamics (PK) and preliminary anti-tumor activity in subjects with advanced solid tumors. Subjects with all histologic types of solid tumors are eligible for the study. However, the preferred tumor types for enrollment are colorectal cancer (CRC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial cancer, endometrial cancer, and gastroesophageal junction (GEJ) or gastric adenocarcinoma. Tumor prostaglandin production and downstream signaling in both tumor cells and other cell types, including immune suppressive cell population in the tumor microenvironment, is thought to be a principal driver of progression in each of these selected malignancies. To be eligible, subjects must have no remaining standard therapy known to confer clinical benefit.

The study is composed of 3 stages. The Dose-Escalation stage will determine the MTD of single-agent TPST-1495 administered twice a day (BID). The Schedule and Dose Optimization stage will evaluate alternative TPST-1495 single-agent administration schedules and determine an RP2D for the selected schedule. This arm will also evaluate TPST-1495 in combination with pembrolizumab. The Expansion stage will evaluate the activity of TPST-1495 as a single agent and in combination with pembrolizumab at the selected schedule and dose in disease-specific cohorts and in a basket cohort in subjects selected for an activating mutation in PIK3Ca.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

175 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Intervention Model Description:

open-label dose escalation, schedule and dose optimization, and dose expansionopen-label dose escalation, schedule and dose optimization, and dose expansion

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Actual Study Start Date :

May 6, 2020

Anticipated Primary Completion Date :

Apr 1, 2024

Anticipated Study Completion Date :

Oct 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: TPST-1495 monotherapy dose escalation Subjects will receive escalating doses of TPST-1495 administered orally twice daily until maximum tolerated dose is reached or until disease progression	Drug: TPST-1495 twice daily TPST-1495 administered orally twice daily
Experimental: TPST-1495 monotherapy dose and schedule optimization Subjects will receive alternative TPST-1495 administration schedules until RP2D for the selected schedule is determined or until disease progression.	Drug: TPST-1495 once daily or on intermittent schedule TPST-1495 administered orally once daily or on intermittent schedule
Experimental: TPST-1495 monotherapy dose expansion Subjects will receive selected dose regimen from dose and schedule optimization stage until disease progression	Drug: TPST-1495 once daily or on intermittent schedule TPST-1495 administered orally once daily or on intermittent schedule
Experimental: TPST-1495 in combination with pembrolizumab dose and schedule optimization Subjects will receive alternative TPST-1495 administration schedules in combination with pembrolizumab until RP2D for the selected schedule is determined or until disease progression.	Drug: TPST-1495 once daily or on intermittent schedule TPST-1495 administered orally once daily or on intermittent schedule Drug: Pembrolizumab Pembrolizumab dosed per label recommendations Other Names: Keytruda
Experimental: TPST-1495 in combination with pembrolizumab dose expansion Subjects will receive selected dose regimen from dose and schedule optimization stage until disease progression	Drug: TPST-1495 once daily or on intermittent schedule TPST-1495 administered orally once daily or on intermittent schedule Drug: Pembrolizumab Pembrolizumab dosed per label recommendations Other Names: Keytruda

Outcome Measures

Primary Outcome Measures

Determination of maximum tolerated dose and/or recommended Phase 2 dose (RP2D) and optimum dose schedule for TPST-1495 as a single agent and in combination with pembrolizumab [From start of treatment to treatment termination visit, up to 24 months]
Determination of maximum tolerated dose and/or recommended Phase 2 dose (RP2D) and optimum dose schedule for TPST-1495 as a single agent and in combination with pembrolizumab based on dose limiting toxicities

Secondary Outcome Measures

Incidence of adverse events and serious adverse events as assessed by NCI-CTCAE v.5.0 [From start of treatment to treatment termination visit, up to 24 months]
Incidence of treatment-emergent adverse events and serious adverse events for TPST-1495
Assess pharmacokinetics: maximum serum concentration (Cmax) [From start of treatment to treatment termination visit, up to 24 months]
Maximum serum concentration (Cmax) of TPST-1495
Assess pharmacokinetics: area under the serum concentration-time curve (AUC) [From start of treatment to treatment termination visit, up to 24 months]
Area under the serum concentration-time curve (AUC) of TPST-1495
Assess pharmacokinetics: Clearance (CL) [From start of treatment to treatment termination visit, up to 24 months]
Clearance (CL) of TPST-1495
Assess pharmacokinetics: terminal elimination half-life (t 1/2) [From start of treatment to treatment termination visit, up to 24 months]
Terminal elimination half-life (t 1/2) of TPST-1495
Overall response rate (ORR) using RECIST version 1.1 [From start of treatment to treatment termination visit, up to 24 months]
Preliminary efficacy of TPST-1495 as a single agent and in combination with pembrolizumab as assessed by overall response rate (ORR) using RECIST version 1.1
Progression free survival (PFS) [From start of treatment to treatment termination visit, up to 24 months]
Preliminary efficacy of TPST-1495 as a single agent and in combination with pembrolizumab as assessed by progression free survival (PFS)
Duration of response (DoR) [From start of treatment to treatment termination visit, up to 24 months]
Preliminary efficacy of TPST-1495 as a single agent and in combination with pembrolizumab as assessed by duration of response (DoR)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Subjects must meet all the following inclusion criteria to be eligible:

Subjects must have a histologically-confirmed malignancy that is metastatic or unresectable for which there is no remaining standard therapy known to confer clinical benefit. While all solid tumor types are eligible for the dose-escalation and dose-finding portions of the study, there is a preference to enroll patients with colorectal cancer, squamous cell carcinoma of the head and neck, urothelial cancer, endometrial cancer, NSCLC, and gastric or gastroesophageal junction adenocarcinoma. The expansion cohorts are limited to the following tumor types: endometrial, SCCHN, CRC, and tumors with an activating mutation in PIK3Ca.
Subjects must have a tumor that is at least 1 cm in a single dimension and is radiographically apparent on CT or MRI.
Eastern Cooperative Oncology Group performance status of 0 or 1 at treatment initiation.
Life expectancy estimated to be ≥ 12 weeks
Adequate organ and marrow function (subjects must not have received transfusions or growth factor support within 1 month prior to first dose of investigational product) as defined below:

Albumin ≥ 3.0 g/dL
Hemoglobin ≥ 10.0 g/dL
Absolute neutrophil count ≥ 1,000/mm3
Platelet count ≥ 100,000/mm3
Bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); for subjects with documented/suspected Gilbert's disease, bilirubin should be ≤ 2 × ULN.
Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN; for subjects with liver metastases, AST or ALT ≤ 5 × ULN
Creatinine ≤ 1.5×ULN OR calculated creatinine clearance (CrCl) ≥ 60 mL/min for subjects with creatinine levels > 1.5× ULN.

Subjects who meet any of the following exclusion criteria will not be eligible to receive investigational product:

Concurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study, a specimen-collection study or the follow-up period of an interventional study.
Received more than 4 doses of nonsteroidal anti-inflammatory drugs or COX-2 inhibitors within 2 weeks prior to study treatment initiation.
History of allergy or hypersensitivity, GI bleed, or ulceration secondary to nonsteroidal anti-inflammatory drugs or COX-2 inhibitors.
History of GI ulcer within 1 year of treatment initiation or history of untreated helicobacter pylori infection. Subjects with history of treated helicobacter pylori infection with confirmation of eradication are eligible
History of diverticulitis or any GI bleed within 2 years of treatment initiation.
Receipt of any anticancer therapy within the following windows:

Small molecule tyrosine kinase inhibitor (TKI) therapy (including investigational) within 2 weeks or 5 half-lives prior to treatment initiation, whichever is longer
Any type of anti-cancer antibody or cytotoxic chemotherapy within 4 weeks prior to treatment initiation
Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before treatment initiation. Patients with clinically relevant ongoing complications from prior radiation therapy are not eligible
Other investigational therapy within 2 weeks or 5 half-lives prior to dosing, whichever is longer

Subjects with active or untreated central nervous system (CNS) metastases
New York Heart Association Classification II, III or IV.
Baseline QTcF > 470 milliseconds
Receipt of live attenuated vaccines within 30 days prior to the first dose of investigational product. (Killed virus or other non-live vaccines are allowed (including most seasonal influenza vaccines, streptococcus pneumonia vaccines, and newly approved COVID-19 vaccines).
Active autoimmune disease or inflammatory disorders including inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) requiring systemic treatment (i.e., with use of disease modifying agents, systemic corticosteroids or immunosuppressive drug) within 2 years prior to treatment initiation.
Known human immunodeficiency virus (HIV) infection, active Hepatitis B (HBV), or hepatitis C (HCV). Active HBV is defined as a known positive HBsAg result. Active HCV is defined by a known positive HCV antibody result and known quantitative HCV RNA results greater than the lower limits of detection of the assay. Patients receiving antiviral therapy for Hepatitis B or C also are not eligible
Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations including a history of substance abuse that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
Subjects who are receiving anti-coagulant therapy or who are considered to be at increased risk of bleeding (i.e bleeding disorder or coagulopathy).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine	Baltimore	Maryland	United States	21287
2	University of Michigan Rogel Cancer Center	Ann Arbor	Michigan	United States	48109
3	START Midwest	Grand Rapids	Michigan	United States	49546
4	Carolina BioOncology Institute	Huntersville	North Carolina	United States	28078
5	SCRI-OK Stephenson Cancer Center	Oklahoma City	Oklahoma	United States	73104
6	University of Pennsylvania Perelman School of Medicine	Philadelphia	Pennsylvania	United States	19104
7	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	United States	15213
8	Tennessee Oncology	Nashville	Tennessee	United States	37203
9	South Texas Accelerated Research Therapeutics (START)	San Antonio	Texas	United States	78229